Larry J. Schaaf

4.4k total citations
89 papers, 2.8k citations indexed

About

Larry J. Schaaf is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Larry J. Schaaf has authored 89 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 33 papers in Molecular Biology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Larry J. Schaaf's work include Cancer therapeutics and mechanisms (21 papers), Cancer Treatment and Pharmacology (13 papers) and Lung Cancer Research Studies (12 papers). Larry J. Schaaf is often cited by papers focused on Cancer therapeutics and mechanisms (21 papers), Cancer Treatment and Pharmacology (13 papers) and Lung Cancer Research Studies (12 papers). Larry J. Schaaf collaborates with scholars based in United States, New Zealand and France. Larry J. Schaaf's co-authors include Mitch A. Phelps, Michael R. Grever, Gary Elfring, John G. Kuhn, James P. Sams, J. Greg Slatter, Miguel A. Villalona‐Calero, Kristie A. Blum, Amy J. Johnson and John C. Byrd and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Larry J. Schaaf

81 papers receiving 2.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Larry J. Schaaf United States	26	1.5k	1.4k	537	460	362	89	2.8k
Ralf A. Hilger Germany	27	1.2k 0.8×	1.3k 1.0×	618 1.2×	173 0.4×	333 0.9×	83	3.2k
Shuiying Hu United States	32	1.7k 1.1×	1.3k 0.9×	311 0.6×	332 0.7×	314 0.9×	94	3.5k
M. Boisdron‐Celle France	27	2.1k 1.3×	803 0.6×	589 1.1×	205 0.4×	267 0.7×	65	3.1k
Erin R. Gardner United States	25	1.1k 0.7×	1.5k 1.1×	256 0.5×	201 0.4×	281 0.8×	49	2.9k
Catherine Wheeler United States	30	1.7k 1.1×	1.1k 0.8×	520 1.0×	311 0.7×	655 1.8×	73	3.6k
Richard M. Lush United States	26	1.4k 0.9×	1.5k 1.1×	451 0.8×	205 0.4×	292 0.8×	78	3.3k
Dona Alberti United States	30	1.0k 0.7×	1.4k 1.0×	419 0.8×	121 0.3×	273 0.8×	90	2.8k
J Mattern Germany	30	1.5k 1.0×	1.7k 1.2×	520 1.0×	282 0.6×	153 0.4×	140	3.4k
Steven D. Reich United States	26	787 0.5×	1.0k 0.7×	532 1.0×	126 0.3×	210 0.6×	73	2.3k
Sylvia A. Holden United States	31	1.4k 0.9×	2.8k 2.0×	398 0.7×	149 0.3×	248 0.7×	85	4.4k

Countries citing papers authored by Larry J. Schaaf

Since Specialization

Citations

This map shows the geographic impact of Larry J. Schaaf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Larry J. Schaaf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Larry J. Schaaf more than expected).

Fields of papers citing papers by Larry J. Schaaf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Larry J. Schaaf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Larry J. Schaaf. The network helps show where Larry J. Schaaf may publish in the future.

Co-authorship network of co-authors of Larry J. Schaaf

This figure shows the co-authorship network connecting the top 25 collaborators of Larry J. Schaaf. A scholar is included among the top collaborators of Larry J. Schaaf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Larry J. Schaaf. Larry J. Schaaf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Phelps, Mitch A., Thomas E. Stinchcombe, James S. Blachly, et al.. (2014). Erlotinib in African Americans With Advanced Non–Small Cell Lung Cancer: A Prospective Randomized Study With Genetic and Pharmacokinetic Analyses. Clinical Pharmacology & Therapeutics. 96(2). 182–191. 18 indexed citations

Patnaik, Amita, Kyriakos P. Papadopoulos, Anthony W. Tolcher, et al.. (2013). Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 71(6). 1499–1506. 44 indexed citations

Mrózek, Ewa, et al.. (2012). Phase II Trial of Exemestane in Combination With Fulvestrant in Postmenopausal Women With Advanced, Hormone-Responsive Breast Cancer. Clinical Breast Cancer. 12(2). 151–156. 7 indexed citations

Lam, Elaine T., Sanjay Goel, Larry J. Schaaf, et al.. (2011). Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 69(2). 523–531. 15 indexed citations

Blum, William, Rebecca B. Klisovic, Heiko Becker, et al.. (2010). Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias. Journal of Clinical Oncology. 28(33). 4919–4925. 71 indexed citations

Blum, William, Mitch A. Phelps, Rebecca B. Klisovic, et al.. (2010). Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias. Haematologica. 95(7). 1098–1105. 48 indexed citations

Ramaswamy, Bhuvaneswari, Tanios Bekaii‐Saab, Larry J. Schaaf, et al.. (2009). A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 66(1). 151–158. 10 indexed citations

Younis, Islam R., Samuel A. Malone, Henry S. Friedman, Larry J. Schaaf, & William P. Petros. (2008). Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma. Cancer Chemotherapy and Pharmacology. 63(3). 517–524. 25 indexed citations

Xu, Yiqing, Jill Kolesar, Larry J. Schaaf, et al.. (2008). Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies. Cancer Chemotherapy and Pharmacology. 63(6). 1073–1082. 7 indexed citations

10.

Liu, Qing, Amy J. Johnson, Natarajan Muthusamy, et al.. (2008). Development and Validation of a Highly Sensitive Liquid Chromatography/Mass Spectrometry Method for Simultaneous Quantification of Lenalidomide and Flavopiridol in Human Plasma. Therapeutic Drug Monitoring. 30(5). 620–627. 28 indexed citations

11.

Pitot, Henry C., Alex A. Adjei, Joel M. Reid, et al.. (2005). A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 58(2). 165–172. 23 indexed citations

12.

Rothenberg, Mace L., John G. Kuhn, Larry J. Schaaf, et al.. (2001). Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. Annals of Oncology. 12(11). 1631–1641. 32 indexed citations

13.

Sloan, Jeff A., Philip J. Atherton, Joel M. Reid, et al.. (2001). Limited sampling models for CPT-11, SN-38, and SN-38 glucuronide. Cancer Chemotherapy and Pharmacology. 48(3). 241–249. 6 indexed citations

14.

Slatter, J. Greg, Larry J. Schaaf, James P. Sams, et al.. (2000). Pharmacokinetics, Metabolism, and Excretion of Irinotecan (CPT-11) Following I.V. Infusion of [14C]CPT-11 in Cancer Patients. Drug Metabolism and Disposition. 28(4). 423–433. 241 indexed citations

15.

Saltz, Leonard B., David R. Spriggs, Larry J. Schaaf, et al.. (1998). Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors.. Journal of Clinical Oncology. 16(12). 3858–3865. 48 indexed citations

16.

Burris, Howard A., Véronique Dièras, Mehmet Tunca, et al.. (1997). Phase I study with the DNA sequence-specific agent adozelesin. Anti-Cancer Drugs. 8(6). 588–596. 22 indexed citations

17.

Strong, Michelle, Larry J. Schaaf, Marvin C. Pankaskie, & Dennis H. Robinson. (1994). Shelf-lives and factors affecting the stability of morphine sulphate and meperidine (pethidine) hydrochloride in plastic syringes for use in patient-controlled analgesic devices. Journal of Clinical Pharmacy and Therapeutics. 19(6). 361–369. 12 indexed citations

18.

Schaaf, Larry J., B. R. Dobbs, I. Ralph Edwards, & D.G. Perrier. (1988). The pharmacokinetics of doxifluridine and 5-fluorouracil after single intravenous infusions of doxifluridine to patients with colorectal cancer. European Journal of Clinical Pharmacology. 34(5). 439–443. 12 indexed citations

19.

Schaaf, Larry J., B. R. Dobbs, I. Ralph Edwards, & D.G. Perrier. (1988). The in vitro stability of doxifluridine in whole blood and plasma. European Journal of Clinical Pharmacology. 34(5). 533–534. 5 indexed citations

20.

Schaaf, Larry J., et al.. (1987). Influence of smoking and gender on the disposition kinetics of metoprolol. European Journal of Clinical Pharmacology. 33(4). 355–361. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact